Annovis Bio Inc. Focuses on Alzheimer’s and Parkinson’s Drug Development

Annovis Bio, Inc., a biotechnology company headquartered in Berwyn, Pennsylvania, continues to make strides in the healthcare sector with its focus on developing treatments for Alzheimer’s and Parkinson’s diseases. The company is particularly noted for its work on orphan indications, including dementia and Alzheimer’s in Down syndrome. Annovis Bio’s efforts are concentrated within the state of Pennsylvania, where it serves its customer base.

As of June 22, 2025, Annovis Bio’s stock closed at $2.64 on the New York Stock Exchange, where it is publicly traded. The company’s market capitalization stands at approximately $52.6 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $17.88 on July 8, 2024, and a low of $1.11 on April 8, 2025.

Annovis Bio’s commitment to addressing complex neurological conditions positions it as a key player in the biotechnology sector. The company’s innovative approach to drug development aims to provide new therapeutic options for patients suffering from these debilitating diseases. For more detailed information on Annovis Bio’s activities and developments, interested parties can visit their website at www.annovisbio.com .